Julie Yu first joined Amicus in January 2008 and currently serves as Chief Program Officer. She brings over 15 years of experience in the drug development industry, focused on program management and clinical operations. After joining Amicus in 2008, she took on increasingly senior roles including overseeing the Galafold® registrational studies. In her current capacity, Dr. Yu provides operational oversight across all development activities, including direct responsibility for Clinical Operations, Regulatory Affairs and Program Management. Prior to joining Amicus, Dr. Yu worked in project management at Merck & Co. Inc., and Biovail, and also previously worked in drug discovery and bioinformatics.
Dr. Yu received a B.Sc. in Immunology and an M.Sc. in Cardiovascular Pathology from the University of Toronto, Canada, a Ph.D. in Clinical Pharmacology from Cambridge University, UK, and an MBA focusing on Strategy, Change Management and Leadership from NYU Langone School of Business. She has been certified as a Project Management Professional since 2005.